APA (7th ed.) Citation

Douma, L. H., Lalezari, F., van der Noort, V., de Vries, J. F., Monkhorst, K., Smesseim, I., . . . de Gooijer, C. J. (2023). Pembrolizumab plus lenvatinib in second-line and third-line patients with pleural mesothelioma (PEMMELA): A single-arm phase 2 study. Lancet Oncology, 24(11), 1219. https://doi.org/10.1016/S1470-2045(23)00446-1

Chicago Style (17th ed.) Citation

Douma, Li-Anne H., et al. "Pembrolizumab Plus Lenvatinib in Second-line and Third-line Patients with Pleural Mesothelioma (PEMMELA): A Single-arm Phase 2 Study." Lancet Oncology 24, no. 11 (2023): 1219. https://doi.org/10.1016/S1470-2045(23)00446-1.

MLA (9th ed.) Citation

Douma, Li-Anne H., et al. "Pembrolizumab Plus Lenvatinib in Second-line and Third-line Patients with Pleural Mesothelioma (PEMMELA): A Single-arm Phase 2 Study." Lancet Oncology, vol. 24, no. 11, 2023, p. 1219, https://doi.org/10.1016/S1470-2045(23)00446-1.